Ziconotide: a new option for intrathecal analgesia

• Wermeling D , M Drass, D Elliset al.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol.43, 624–636 (2003).
   PubMed Web of Science ®Google Scholar
• Markman J , DworkinR: Ion channel targets and treatment efficacy in neuropathic pain.J. Pain7(Suppl. 1), S38–S47 (2006).
   PubMed Web of Science ®Google Scholar
• Miljanich GP : Ziconotide: Neuronal calcium channel blocker for treating severe chronic pain.Curr. Med. Chem.11, 3029–3040 (2004).
   PubMed Web of Science ®Google Scholar
• Shields D , MontenegroR, RagusaM: Chemical stability of admixtures combining ziconotide with morphine or hydromorphone during simulated intrathecal administration.Neuromodulation8(4), 257–263 (2005).
   PubMed Web of Science ®Google Scholar
• Yaksh T : calcium channels as therapeutic targets in neuropathic pain.J. Pain7(1), S13–S30 (2006).
   PubMed Web of Science ®Google Scholar
• Kristipati R , NadasdiL, Tarczy-HornochKet al.: Characterization of the binding of omega-conopeptides to different classes of non-L-type neuronal calcium channels.Mol. Cell. Neurosci.5, 219–228 (1994).
   PubMed Web of Science ®Google Scholar
• Olivera BM , CruzLJ, de Santos Vet al.: Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using co-conotoxin from Conus magus venom. Biochemistry26, 2086–2090 (1987).
   PubMed Web of Science ®Google Scholar
• Wang YX , BowersoxSS: analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels.CNS Drug Reviews6,1, 1–20 (2000).
   Google Scholar
• Gohil K , BellJR, RamachandranJet al.: Neuroanatomical distribution of receptors for a novel voltage-sensitive calcium-channel antagonist, SNX-230 (omega-conopeptide MVIIC).Brain Res.653(1–2), 258–266 (1994).
   PubMed Web of Science ®Google Scholar
• Bowersox S , SinghT, NadasdiLet al.: Cardiovascular effects of ω-conopeptides in conscious rats: Mechanisms of action.J. Cardiovasc. Pharmacol.20(5), 756–764 (1992).
   PubMed Web of Science ®Google Scholar
• McGuire D , BowersoxS, FellmannJet al.: Sympatholysis after neuron-specific, N-type, voltage- sensitive calcium channel blockade: First demonstration of N-channel function in humans.J. Cardiovasc. Pharmacol.30(3), 400–403 (1997).
   PubMed Web of Science ®Google Scholar
• Yong-Xiang W , BowersoxS: Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels.CNS Drug Reviews6(1), 1–20 (2000).
   Google Scholar
• Malmberg A , YakshT: Voltage-sensitive calcium channels in spinal nociceptive processing: blockade of N-and P-type channels inhibits formalin-induced nociception.J. Neurosci.14(8), 4882–4890 (1994).
   PubMed Web of Science ®Google Scholar
• Malmberg A , YakshT: Effect of continuous intrathecal infusion of ω-conopeptides, N-type calcium channel blockers, on behaviour and antinociception in the formalin and hot-plate test in rats.Pain60(1), 83–90 (1995).
   PubMed Web of Science ®Google Scholar
• Wang YX , GaoD, PettusMet al.: Effects of intrathecal administration of ziconotide, a selective N-type calcium channel blocker on mechanical allodynia and heat hyperalgesia in a rat model of postoperative pain.Pain84(2–3), 271–281 (2000).
   PubMed Web of Science ®Google Scholar
• Pirec V , LauritoC, LuYet al.: The combined effects of n-type calcium channel blockers and morphine on Aδ versus C fiber mediated nociception.Anesth. Analg.92(1), 239–243 (2001).
   PubMed Web of Science ®Google Scholar
• Atanassoff PG , HartmannsgruberMW, ThrasherJet al.: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain.Reg. Anesth. Pain. Med.25(3), 274–278 (2000).
   PubMed Web of Science ®Google Scholar
• Staats PS , YearwoodT, CharapataSGet al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.J. Am. Med. Assoc.291(1), 63–70 (2004)
   PubMed Web of Science ®Google Scholar
• Wallace MS , CharapataSG, FisherRet al.: Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial.Neuromod.9(2), 75–86 (2006).
   PubMed Web of Science ®Google Scholar
• Rauck R , WallaceM, LeongMet al.: A randomized, double blind, placebo controlled study of intrathecal ziconotide in adults with severe chronic pain.J. Pain Symptom Manage.31(5), 393–406 (2006).
   PubMed Web of Science ®Google Scholar
• Staats P , WallaceM, PresleyDet al.: Long-term intrathecal ziconotide effectiveness in chronic malignant and non malignant pain (abstract no. 785).J. Pain5(3 Suppl.1), S55 (2004).
   Google Scholar
• Fisher R , EllisD, MarmonTet al.: An open label, multicentre study of the safety and efficacy of adding intrathecal (IT) ziconotide to stable dose IT morphine in patients with severe chronic pain.Proceedings of the 22nd Annual Meeting of the American Academy of Pain Medicine. San Diego, CA, USA (2006).
   Google Scholar
• Staats P , CharapataS, RoyalMet al.: The safety profile of intrathecal ziconotide: a new non-opioid analgesic.Presented at the 19th Annual Scientific Meeting of the American Pain Society. Atlanta, USA (2000) (Abstract 839).
   Google Scholar
• Dissanayake S , RoyalM, WallaceM: Incidence of adverse in patients on long-term (at least 6 months) ziconotide (abstract no.886)J. Pain73(4), (Suppl.1) S2 (2003).
   Google Scholar
• Lyseng-Williamson K , PerryC: Ziconotide.CNS Drugs20(4), 331–338 (2006).
   Google Scholar
• Fisher R , HassenbuschS, KramesEet al.: A consensus statement regarding the present suggested titration for prialt (ziconotide).Neuromodulation8(3), 153–154 (2005).
   PubMed Web of Science ®Google Scholar

Website

• PRIALT®, Summary of Product Characteristics www.emea.eu.int/humandocs/Humans/EPAR/prialt/prialt.htm (Accessed July 2006)
   Google Scholar